ESH 2017 | An overview of immunotherapies for leukemia
Ravi Majeti
• 12 Oct 2017
As research into the different aspects of treating leukemia develops there will be an increase in the number of targeted medications available, enabling more patients to be treated effectively. In this interview, Ravindra Majeti, MD, PhD, from Stanford University, Stanford, CA, provides us with an overview of the various forms of immunotherapies for leukemia, their side effects and the exclusive nature of certain types. This interview was recorded at the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).
